Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
V. Thatikonda, H. Lu, S. Jurado…·M. H. Hofmann
This study shows that combining KRASG12C and SOS1 inhibitors improves anti-tumor response and delays resistance in KRASG12C-driven cancers.